Table 1 Demographic features, clinical records, and immunomodulatory therapy of the AR population
Parameters | csDMARD n = 73 | cs+bDMARD n = 48 | ||||
|---|---|---|---|---|---|---|
1–5 years n = 18 | > 5–9 years n = 37 | ≥ 10 years n = 18 | 1–5 years n = 10 | > 5–9 years n = 25 | ≥ 10 years n = 13 | |
Gender (F/M) | 17/01 | 35/02 | 15/03 | 09/01 | 23/02 | 13/00 |
Age (years) | 58 (31–78) | 53 (26–86) | 49 (23–81) | 55 (28–75) | 60 (40–82) | 54 (29–80) |
Disease duration (months) | 99 (12–432) | 114 (12–348) | 84 (12–480) | 210 (96–298) | 144 (72–370) | 168 (96–288) |
csDMARD dose | ||||||
MTX (2.5– 25 mg/week) | 17 mg (14/18) | 16 mg (35/37) | 18 mg (12/18) | 23 mg (05/10) | 17 mg (14/25) | 17 mg (04/13) |
LEF (standard dose/day) | 20 mg (06/18) | 20 mg (19/37) | 20 mg (09/18) | 20 mg (05/10) | 20 mg (12/25) | 20 mg (06/13) |
SSZ (1000–3000 mg/day) | 1500 mg (02/18) | – | 2300 mg (03/18) | – | 1000 mg (02/25) | 1200 mg (05/13) |
AML (150–400 mg/day) | 275 mg (04/18) | 340 mg (05/37) | – | – | 150 mg/day (01/25) | 275 mg/day (02/13) |
AZA (2–3 mg/kg/day) | – | – | – | 150 mg (01/10) | – | – |
CYC (3–5 mg/kg/day) | – | – | – | – | – | 200 mg (01/13) |
bDMARD dose | ||||||
ADA (standard dose/eow) | – | – | – | 40 mg (01/10) | 40 mg (02/25) | 40 mg (01/13) |
CTZ (standard dose/month) | – | – | – | 400 mg (02/10) | – | 400 mg (01/13) |
ETN (standard dose/week) | – | – | – | 50 mg (05/10) | 50 mg (05/25) | 50 mg (04/13) |
GOL (standard dose/month) | – | – | – | – | 50 mg (02/25) | 50 mg (03/13) |
IFX (3–5 mg/kg/e8w) | – | – | – | 300 mg (01/10) | 233 mg (06/25) | – |
TCZ (8 mg/kg/month) | – | – | – | – | 496 mg (05/25) | 480 mg (02/13) |
ABT (10 mg/kg/month) | – | – | – | – | 750 mg (03/25) | 750 mg (01/13) |
RTX (standard dose/e6m) | – | – | – | 1000 mg (01/10) | 1000 mg (02/25) | 1000 mg (01/13) |
GC | ||||||
PDN (2.5–40 mg/day) | 7.5 mg (04/18) | 13.6 mg (06/37) | 8.2 mg (07/18) | 6.7 mg (03/10) | 10.8 mg (06/25) | 7.0 mg (05/13) |